S.-A. Im

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

Yung‐Jue Bang, Giuseppe Giaccone, S.-A. Im et al. · Annals of Oncology · 2017 · 225 citations · Full text

Medicine, Oncology, Pharmacology +16

Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to Trastuzumab

Hye Jung Chang, Sae‐Won Han, Do‐Youn Oh et al. · Japanese Journal of Clinical Oncology · 2011 · 65 citations · Full text

Medicine, Oncology, Chemotherapy +14

Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma

J. O. Lee, Kuhn‐Uk Lee, Do‐Youn Oh et al. · Annals of Oncology · 2009 · 63 citations · Full text

Medicine, Oncology, Pharmacology +14

Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment

Hyeong‐Gon Moon, Wonshik Han, Joon Woo Lee et al. · Annals of Oncology · 2009 · 60 citations · Full text

Medicine, Oncology, Radiology +17

Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)

RS Finn, Yuqiu Jiang, Hope S. Rugo et al. · Annals of Oncology · 2016 · 56 citations · Full text

Medicine, Oncology, Pharmacology +17